PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock
59.42 USD
+0.25 (+0.42%)
59.42 USD
0 (0%)
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. PBH gets an excellent profitability rating and is at the same time showing great financial health properties. PBH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
In the past year PBH had a positive cash flow from operations.
PBH had positive earnings in 4 of the past 5 years.
PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.21%, PBH belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
PBH's Return On Equity of 11.48% is amongst the best of the industry. PBH outperforms 86.46% of its industry peers.
With an excellent Return On Invested Capital value of 7.95%, PBH belongs to the best of the industry, outperforming 85.94% of the companies in the same industry.
PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is significantly below the industry average of 13.48%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH has a better Profit Margin (19.02%) than 91.15% of its industry peers.
PBH's Profit Margin has improved in the last couple of years.
The Operating Margin of PBH (31.15%) is better than 94.27% of its industry peers.
PBH's Operating Margin has been stable in the last couple of years.
PBH's Gross Margin of 56.13% is fine compared to the rest of the industry. PBH outperforms 65.63% of its industry peers.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
PBH has an Altman-Z score of 2.55. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.55, PBH is doing good in the industry, outperforming 67.71% of the companies in the same industry.
The Debt to FCF ratio of PBH is 3.79, which is a good value as it means it would take PBH, 3.79 years of fcf income to pay off all of its debts.
PBH has a better Debt to FCF ratio (3.79) than 85.42% of its industry peers.
PBH has a Debt/Equity ratio of 0.55. This is a neutral value indicating PBH is somewhat dependend on debt financing.
PBH's Debt to Equity ratio of 0.55 is on the low side compared to the rest of the industry. PBH is outperformed by 64.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.55 |
ROIC/WACC0.96
WACC8.26%
2.3 Liquidity
A Current Ratio of 4.38 indicates that PBH has no problem at all paying its short term obligations.
The Current ratio of PBH (4.38) is better than 63.54% of its industry peers.
A Quick Ratio of 2.99 indicates that PBH has no problem at all paying its short term obligations.
PBH has a Quick ratio (2.99) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.15%, which is quite good.
PBH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.88% yearly.
Looking at the last year, PBH shows a small growth in Revenue. The Revenue has grown by 1.10% in the last year.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
3.2 Future
The Earnings Per Share is expected to grow by 3.45% on average over the next years.
The Revenue is expected to grow by 1.11% on average over the next years.
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.03 indicates a correct valuation of PBH.
Based on the Price/Earnings ratio, PBH is valued cheaper than 87.50% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.45. PBH is valued slightly cheaper when compared to this.
PBH is valuated correctly with a Price/Forward Earnings ratio of 12.32.
PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 83.85% of the companies in the same industry.
PBH is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.46, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.03 | ||
| Fwd PE | 12.32 |
4.2 Price Multiples
88.02% of the companies in the same industry are more expensive than PBH, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 88.54% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.92 | ||
| EV/EBITDA | 10 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)19.42
PEG (5Y)1.47
EPS Next 2Y3.17%
EPS Next 3Y2.82%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
59.42
+0.25 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.07%
Inst Owner Change-0.69%
Ins Owners1.29%
Ins Owner Change1.87%
Market Cap2.92B
Revenue(TTM)1.14B
Net Income(TTM)213.00M
Analysts84
Price Target79.05 (33.04%)
Short Float %3.12%
Short Ratio3.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)-3.35%
PT rev (3m)-10.02%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)-9.33%
EPS NY rev (1m)-0.25%
EPS NY rev (3m)-5.34%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-2.43%
Revenue NY rev (1m)-0.18%
Revenue NY rev (3m)-3.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.03 | ||
| Fwd PE | 12.32 | ||
| P/S | 2.61 | ||
| P/FCF | 10.92 | ||
| P/OCF | 10.6 | ||
| P/B | 1.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10 |
EPS(TTM)4.56
EY7.67%
EPS(NY)4.82
Fwd EY8.11%
FCF(TTM)5.44
FCFY9.16%
OCF(TTM)5.6
OCFY9.43%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)19.42
PEG (5Y)1.47
Graham Number62.2
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexgc growth 3Y-14.1%
ROICexgc growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.55 |
F-Score8
WACC8.26%
ROIC/WACC0.96
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.15%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%-1.83%
EPS Next Y0.67%
EPS Next 2Y3.17%
EPS Next 3Y2.82%
EPS Next 5Y3.45%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-3.41%
Revenue Next Year-2.36%
Revenue Next 2Y0.13%
Revenue Next 3Y0.46%
Revenue Next 5Y1.11%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year7.03%
EBIT Next 3Y3.48%
EBIT Next 5Y2.99%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%
PRESTIGE CONSUMER HEALTHCARE / PBH FAQ
What is the ChartMill fundamental rating of PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PBH.
What is the valuation status for PBH stock?
ChartMill assigns a valuation rating of 6 / 10 to PRESTIGE CONSUMER HEALTHCARE (PBH). This can be considered as Fairly Valued.
How profitable is PRESTIGE CONSUMER HEALTHCARE (PBH) stock?
PRESTIGE CONSUMER HEALTHCARE (PBH) has a profitability rating of 7 / 10.
How financially healthy is PRESTIGE CONSUMER HEALTHCARE?
The financial health rating of PRESTIGE CONSUMER HEALTHCARE (PBH) is 7 / 10.
What is the earnings growth outlook for PRESTIGE CONSUMER HEALTHCARE?
The Earnings per Share (EPS) of PRESTIGE CONSUMER HEALTHCARE (PBH) is expected to grow by 0.67% in the next year.